Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A pre-specified analysis of MAPLE-HCM
Mavacamten treatment in obstructive hypertrophic cardiomyopathy for up to 30 weeks: An integrated analysis of cardiac magnetic resonance data from a diverse population in randomized clinical trials
Efficacy and safety of long-term treatment with aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: results from FOREST-HCM